There are primarily two protease inhibitors in bronchial mucus: alpha,-AT and an acid stable low molecular weight protease inhibitor (LMI), which has been described by Hochstrasser and associates (8, 21, 22) . It is thought that these inhibitors make a major contribution in defending the bronchial epithelium against attack by proteolytic enzymes.
LMI, which is not present in the circulation, accounts for at least 70% of the total inhibiting capacity of bronchial mucus against granulocyte proteases (8, 31) . tween the localization of the protease inhibitor and lysozyme was observed.
Our observations indicate that the inhibitor may be present together with lysozyme as a secretory product in the serous cell granules. The possible consequences of the coexistence of these two proteins in the defense mechanism of the respiratory tract is discussed. 
